Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Ceberg

Crister Ceberg

Professor

Ceberg

Combined anti-C1-INH and radiotherapy against glioblastoma

Författare

  • Emma Liljedahl
  • Elise Konradsson
  • Emma Gustafsson
  • Karolina Förnvik Jonsson
  • Jill K. Olofsson
  • Kurt Osther
  • Crister Ceberg
  • Henrietta Nittby Redebrandt

Summary, in English

Background: A more effective immune response against glioblastoma is needed in order to achieve better tumor control. Radiotherapy can induce anti-tumor mediated immune reactions, in addition to its dose response effects. The complement system can function as a bridge between innate and adaptive immune responses. Combining radiotherapy and complement activating therapy is theoretically interesting. Methods: Radiotherapy at 8 Gy × 2 was combined with treatment against C1-inhibitor (C1-INH), a potent inhibitor of activation of the classical pathway of the complement system. Anti-C1-INH was delivered as intratumoral injections. Fully immunocompetent Fischer 344 rats with NS1 glioblastoma tumors were treated. Survival was monitored as primary outcome. Models with either intracranial or subcutaneous tumors were evaluated separately. Results: In the intracranial setting, irradiation could prolong survival, but there was no additional survival gain as a result of anti-C1-INH treatment. In animals with subcutaneous tumors, combined radio-immunotherapy with anti-C1-INH and irradiation at 8 Gy × 2 significantly prolonged survival compared to control animals, whereas irradiation or anti-C1-INH treatment as single therapies did not lead to significantly increased survival compared to control animals. Conclusions: Anti-C1-INH treatment could improve the efficacy of irradiation delivered at sub-therapeutic doses and delay tumor growth in the subcutaneous tumor microenvironment. In the intracranial setting, the doses of anti-C1-INH were not enough to achieve any survival effect in the present setting.

Avdelning/ar

  • Neurokirurgi
  • Medicinsk strålningsfysik, Lund
  • Radiotherapy Physics
  • Human neural utvecklingsbiologi
  • StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
  • Rausinglaboratoriet i Lund - Tumörsektionen
  • LU profilområde: Ljus och material

Publiceringsår

2023

Språk

Engelska

Publikation/Tidskrift/Serie

BMC Cancer

Volym

23

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

BioMed Central (BMC)

Ämne

  • Cancer and Oncology

Nyckelord

  • Complement system
  • Glioblastoma
  • Radiotherapy

Status

Published

Forskningsgrupp

  • Radiotherapy Physics
  • Human Neural Developmental Biology
  • Rausing laboratory of Lund - Tumor section

ISBN/ISSN/Övrigt

  • ISSN: 1471-2407